Health professionals’ attitudes toward medications for opioid use disorder

References

• Manchikanti L, Helm S, Fellows B, et al. Opioid epidemic in the United States. Pain Physician. 2012;15(3):ES9–ES38.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Results from the 2018 National Survey on Drug Use and Health: Detailed Tables. North Bethesda, MD: Center for Behavioral Health Statistics and Quality; 2019.
   Google Scholar
• International Narcotics Control Board. Narcotic Drugs: Estimated Word Requirements for 2018, Statistics for 2016. New York, NY: United Nations; 2017.
   Google Scholar
• Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54(10):901–906.
   PubMed Web of Science ®Google Scholar
• Pollack HA. So prescription opioid disorders are a $78.5 billion problem. Med Care. 2016;54(10):899–900.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta‐analysis of cohort studies. Addiction. 2011;106(1):32–51.
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–2066.
   PubMed Web of Science ®Google Scholar
• Baser O, Chalk M, Fiellin DA, Gastfriend DR. Cost and utilization outcomes of opioid-dependence treatments. Am J Managed Care. 2011;17(8):S235.
   PubMedGoogle Scholar
• Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. North Bethesda, MD: SAMHSA; 2005.
   Google Scholar
• Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207–225.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O’Connor PG. Primary care–based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(12):1947–1954.
   PubMed Web of Science ®Google Scholar
• Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283(10):1303–1310.
   PubMed Web of Science ®Google Scholar
• Rettig RA, Yarmolonsky A. Federal Regulation of Methadone Treatment. Washington, DC: National Academy; 1995.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Buprenorphine. 2021. https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine. Accessed February 26, 2021.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Become a buprenorphine waivered practitioner. 2021. https://www.samhsa.gov/medication-assisted-treatment/become-buprenorphine-waivered-practitioner. Accessed February 26, 2021.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Naltrexone. 2020. https://www.samhsa.gov/medication-assistedtreatment/medications-counseling-related-conditions/naltrexone. Accessed February 26, 2021.
   Google Scholar
• Syed YY, Keating GM. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients. CNS Drugs. 2013;27(10):851–861.
   PubMed Web of Science ®Google Scholar
• Lee JD, Nunes EV, Jr Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial. The Lancet. 2018;391(10118):309–318.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Federal Guidelines for Opioid Treatment Programs. North Bethesda, MD: SAMHSA; 2015.
   Google Scholar
• Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2004;4:CD004147.
   Google Scholar
• Brown A. A systematic review of psychosocial interventions in treatment of opioid addiction. J Soc Work Pract Addict. 2018;18(3):249–269.
   Web of Science ®Google Scholar
• Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238–1246.
   PubMed Web of Science ®Google Scholar
• Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010;30(2):155–166.
   PubMed Web of Science ®Google Scholar
• Martin SA, Chiodo LM, Bosse JD, Wilson A. The next stage of buprenorphine care for opioid use disorder. Ann Intern Med. 2018;169(9):628–635.
   PubMed Web of Science ®Google Scholar
• Carroll KM, Weiss RD. The role of behavioral interventions in buprenorphine maintenance treatment: a review. AJP. 2017;174(8):738–747.
   Google Scholar
• Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–e63.
   PubMed Web of Science ®Google Scholar
• Wu L-T, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117–127.
   PubMed Web of Science ®Google Scholar
• Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36(1):559–574.
   PubMed Web of Science ®Google Scholar
• Madden LM, Farnum SO, Eggert KF, et al. An investigation of an open‐access model for scaling up methadone maintenance treatment. Addiction. 2018;113(8):1450–1458.
   PubMed Web of Science ®Google Scholar
• Murthy VH. Ending the opioid epidemic—a call to action. N Engl J Med. 2016;375(25):2413–2415.
   PubMed Web of Science ®Google Scholar
• Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. Clin Infect Dis. 2006;43(4):S197–S215.
   PubMed Web of Science ®Google Scholar
• Schwartz RP, Gryczynski J, O’Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. Am J Public Health. 2013;103(5):917–922.
   PubMed Web of Science ®Google Scholar
• Jones EB. Medication‐assisted opioid treatment prescribers in federally qualified health centers: capacity lags in rural areas. J Rural Health. 2018;34(1):14–22.
   PubMed Web of Science ®Google Scholar
• Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211–1212.
   PubMed Web of Science ®Google Scholar
• Wakeman SE. Using science to battle stigma in addressing the opioid epidemic: opioid agonist therapy saves lives. Am J Med. 2016;129(5):455–456.
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Rich JD. Barriers to medications for addiction treatment: how stigma kills. Subst Use Misuse. 2018;53(2):330–333.
   PubMed Web of Science ®Google Scholar
• Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder-and its treatment. JAMA. 2014;311(14):1393–1394.
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Rich JD. Barriers to post-acute care for patients on opioid agonist therapy; An example of systematic stigmatization of addiction. J Gen Intern Med. 2017;32(1):17–19.
   PubMed Web of Science ®Google Scholar
• Magrath SM. Medication Assisted Treatment and the Three Legged Stool: Medical Providers, Chemical Dependency Professionals, and Clients [dissertation]. Culver City, CA: Antioch University; 2016.
   Google Scholar
• Trevor E. Attitudes and Beliefs Toward Methadone Maintenance Treatment Among General Practitioners and Nurses [dissertation]. San Francisco, CA: California Institute of Integral Studies; 2011.
   Google Scholar
• Oliva EM, Maisel NC, Gordon AJ, Harris AH. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011;13(5):374–381.
   PubMed Web of Science ®Google Scholar
• Weber EM. Failure of physicians to prescribe pharmacotherapies for addiction: regulatory restrictions and physician resistance. J Health Care Law & Policy. 2010;13:49.
   Google Scholar
• Hadland SE, Park TW, Bagley SM. Stigma associated with medication treatment for young adults with opioid use disorder: a case series. Addict Sci Clin Pract. 2018;13(1):15.
   PubMed Web of Science ®Google Scholar
• Caplehorn JRM, Hartel DM, Irwig L. Measuring and comparing the attitudes and beliefs of staff working in New York methadone maintenance clinics. Subst Use Misuse. 1997;32(4):399–413.
   PubMed Web of Science ®Google Scholar
• Kang SY, Magura S, Nwakeze P, Demsky S. Counselor attitudes in methadone maintenance. J Maintenance Addict. 1998;1(2):41–58.
   Google Scholar
• Forman RF, Bovasso G, Woody G. Staff beliefs about addiction treatment. J Subst Abuse Treat. 2001;21(1):1–9.
   PubMed Web of Science ®Google Scholar
• Tuchman E, Bonuck K, Tommasello A, Drucker E. Office based methadone treatment: a role for community pharmacists. Addict Disord Treat. 2003;2(3):91–96.
   Google Scholar
• Wryobeck JM. The Relative Importance of Client Characteristics in Recommending a Harm Reduction Treatment Strategy: A Policy Capturing Study of Psychologists [dissertation]. Bowling Green, OH: Bowling Green State University; 2003.
   Google Scholar
• Goddard P. Changing attitudes towards harm reduction among treatment professionals: a report from the American Midwest. Int J Drug Policy. 2003;14(3):257–260.
   Google Scholar
• Rosenberg H, Phillips KT. Acceptability and availability of harm-reduction interventions for drug abuse in American substance abuse treatment agencies. Psychol Addict Behav. 2003;17(3):203–210.
   PubMed Web of Science ®Google Scholar
• McCarty D, Rieckmann T, Green C, Gallon S, Knudsen J. Training rural practitioners to use buprenorphine: using the change book to facilitate technology transfer. J Subst Abuse Treat. 2004;26(3):203–208.
   PubMed Web of Science ®Google Scholar
• Knudsen HK, Ducharme LJ, Roman PM, Link T. Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. J Subst Abuse Treat. 2005;29(2):95–106.
   PubMed Web of Science ®Google Scholar
• Merrill JO, Jackson TR, Schulman BA, et al. Methadone medical maintenance in primary care: an implementation evaluation. J Gen Intern Med. 2005;20(4):344–349.
   PubMed Web of Science ®Google Scholar
• Tuchman E, Gregory C, Simson JM, Drucker E. Office-based opioid treatment (OBOT): practitioner’s knowledge, attitudes, and expectations in New Mexico. Addict Disorders Treat. 2005;4(1):11–19.
   Google Scholar
• Arfken CL, Agius E, Dickson MW, Anderson HL, Hegedus AM. Clinicians’ beliefs and awareness of substance abuse treatments in research-and nonresearch-affiliated programs. J Drug Issues. 2005;35(3):547–558.
   Web of Science ®Google Scholar
• McMillan GP, Lapham SC. Staff perspectives on methadone maintenance therapy (MMT) in a large southwestern jail. Addict Res Theory. 2005;13(1):53–63.
   Web of Science ®Google Scholar
• Raisch DW, Fudala PJ, Saxon AJ, et al. Pharmacists’ and technicians’ perceptions and attitudes toward dispensing buprenorphine/naloxone to patients with opioid dependence. J Am Pharm Assoc. 2005;45(1):23–32.
   Google Scholar
• Rich JD, Boutwell AE, Shield DC, et al. Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health. 2005;82(3):411–419.
   PubMed Web of Science ®Google Scholar
• Turner BJ, Laine C, Lin YT, Lynch K. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med. 2005;165(15):1769–1776.
   PubMed Web of Science ®Google Scholar
• Cunningham CO, Sohler NL, McCoy K, Kunins HV. Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Family Medicine Kansas City. 2006;38(5):336.
   PubMed Web of Science ®Google Scholar
• Evans JS. Assessing and Comparing Attitudes toward Addiction and Methadone Treatment [dissertation]. Athens, OH: Ohio University; 2006.
   Google Scholar
• Havranek JE, Stewart JR. Rehabilitation counselors’ attitudes toward harm reduction measures. Journal of Applied Rehabilitation Counseling. 2006;37(1):38–44.
   Google Scholar
• Andrews S, Sorensen JL, Guydish J, Delucchi K, Greenberg B. Knowledge and attitudes about methadone maintenance among staff working in a therapeutic community. J Maintenance Addict. 2005;3(1):47–59.
   PubMedGoogle Scholar
• Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;25(4):91–103.
   PubMed Web of Science ®Google Scholar
• Cunningham CO, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22(9):1325–1329.
   PubMed Web of Science ®Google Scholar
• Fuller BE, Rieckmann T, Nunes EV, et al. Organizational readiness for change and opinions toward treatment innovations. J Subst Abuse Treat. 2007;33(2):183–192.
   PubMed Web of Science ®Google Scholar
• Knudsen HK, Ducharme LJ, Roman PM. The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug Alcohol Depend. 2007;87(2–3):164–174.
   PubMed Web of Science ®Google Scholar
• McCarty D, Fuller BE, Arfken C, et al. Direct care workers in the National Drug Abuse Treatment Clinical Trials Network: characteristics, opinions, and beliefs. Psychiatr Serv. 2007;58(2):181–190.
   PubMed Web of Science ®Google Scholar
• Rieckmann T, Daley M, Fuller BE, Thomas CP, McCarty D. Client and counselor attitudes toward the use of medications for treatment of opioid dependence. J Subst Abuse Treat. 2007;32(2):207–215.
   PubMed Web of Science ®Google Scholar
• Varra AA, Hayes SC. Assessing referrals for pharmacotherapy: a comparison of therapist and client report. J Subst Abuse Treat. 2007;32(4):411–413.
   PubMed Web of Science ®Google Scholar
• Roose RJ, Kunins HV, Sohler NL, Elam RT, Cunningham CO. Nurse practitioner and physician assistant interest in prescribing buprenorphine. J Subst Abuse Treat. 2008;34(4):456–459.
   PubMed Web of Science ®Google Scholar
• Thomas CP, Reif S, Haq S, Wallack SS, Hoyt A, Ritter GA. Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists. Psychiatr Serv. 2008;59(8):909–916.
   PubMed Web of Science ®Google Scholar
• Varra AA, Hayes SC, Roget N, Fisher G. A randomized control trial examining the effect of acceptance and commitment training on clinician willingness to use evidence-based pharmacotherapy. J Consult Clin Psychol. 2008;76(3):449–458.
   PubMed Web of Science ®Google Scholar
• Herbeck DM, Hser YI, Teruya C. Empirically supported substance abuse treatment approaches: a survey of treatment providers’ perspectives and practices. Addict Behav. 2008;33(5):699–712.
   PubMed Web of Science ®Google Scholar
• Fitzgerald J, McCarty D. Understanding attitudes toward use of medication in substance abuse treatment: a multilevel approach. Psychol Serv. 2009;6(1):74–84.
   PubMed Web of Science ®Google Scholar
• Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009;36(3):244–251.
   PubMed Web of Science ®Google Scholar
• Albright J, Ciaverelli R, Essex A, Tkacz J, Ruetsch C. Psychiatrist characteristics that influence use of buprenorphine medication-assisted treatment. J Addict Med. 2010;4(4):197–203.
   PubMed Web of Science ®Google Scholar
• Abraham AJ, Rieckmann T, McNulty T, Kovas AE, Roman PM. Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach. Addict Behav. 2011;36(6):576–583.
   PubMed Web of Science ®Google Scholar
• Agnew CJ. Buprenorphine as an Efficacious Treatment for Opioid Dependency? A Survey of Counselors Attitudes [dissertation]. Athens, OH: Ohio University; 2011.
   Google Scholar
• Rieckmann TR, Kovas AE, McFarland BH, Abraham AJ. A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment. J Subst Abuse Treat. 2011;41(4):374–385.
   PubMed Web of Science ®Google Scholar
• Bride BE, Abraham AJ, Kintzle S, Roman PM. Social workers’ knowledge and perceptions of effectiveness and acceptability of medication assisted treatment of substance use disorders. Soc Work Health Care. 2013;52(1):43–58.
   PubMed Web of Science ®Google Scholar
• Schuman-Olivier Z, Connery H, Griffin ML, et al. Clinician beliefs and attitudes about buprenorphine/naloxone diversion. Am J Addict. 2013;22(6):574–580.
   PubMed Web of Science ®Google Scholar
• Hutchinson E, Catlin M, Andrilla CHA, Baldwin LM, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128–133.
   PubMed Web of Science ®Google Scholar
• Rieckmann TR, Abraham AJ, Kovas AE, McFarland BH, Roman PM. Impact of research network participation on the adoption of buprenorphine for substance abuse treatment. Addict Behav. 2014;39(5):889–896.
   PubMed Web of Science ®Google Scholar
• Roberto AJ, Shafer MS, Marmo J. Predicting substance-abuse treatment providers’ communication with clients about medication assisted treatment: a test of the theories of reasoned action and planned behavior. J Subst Abuse Treat. 2014;47(5):307–313.
   PubMed Web of Science ®Google Scholar
• Suzuki J, Connery HS, Ellison TV, Renner JA. Preliminary survey of office‐based opioid treatment practices and attitudes among psychiatrists never receiving buprenorphine training to those who received training during residency. Am J Addict. 2014;23(6):618–622.
   PubMed Web of Science ®Google Scholar
• DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health. 2015;15(1):3019.
   PubMed Web of Science ®Google Scholar
• Friedmann PD, Wilson D, Knudsen HK, et al. Effect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community corrections. J Subst Abuse Treat. 2015;50:50–58.
   PubMed Web of Science ®Google Scholar
• Aletraris L, Edmond MB, Paino M, Fields D, Roman PM. Counselor training and attitudes toward pharmacotherapies for opioid use disorder. Subst Abus. 2016;37(1):47–53.
   PubMed Web of Science ®Google Scholar
• Estreet A, Archibald P, Tirmazi MT, Goodman S, Cudjoe T. Exploring social work student education: the effect of a harm reduction curriculum on student knowledge and attitudes regarding opioid use disorders. Subst Abus. 2017;38(4):369–375.
   PubMed Web of Science ®Google Scholar
• Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1–7.
   PubMed Web of Science ®Google Scholar
• Kermack A, Flannery M, Tofighi B, McNeely J, Lee JD. Buprenorphine prescribing practice trends and attitudes among New York providers. J Subst Abuse Treat. 2017;74:1–6.
   PubMed Web of Science ®Google Scholar
• Rieckmann T, Moore L, Croy C, Aarons GA, Novins DK. National overview of medication-assisted treatment for American Indians and Alaska natives with substance use disorders. Psychiatr Serv. 2017;68(11):1136–1143.
   PubMed Web of Science ®Google Scholar
• James JR, Gordon LM, Klein JW, Merrill JO, Tsui JI. Interest in prescribing buprenorphine among resident and attending physicians at an urban teaching clinic. Subst Abuse. 2019;40(1):11–13.
   PubMed Web of Science ®Google Scholar
• Jones CM, McCance‐Katz EF. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction. 2019;114(3):471–482.
   PubMed Web of Science ®Google Scholar
• Pytell JD, Buresh ME, Graddy R. Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice. Addict Sci Clin Pract. 2019;14(1):1–7.
   PubMed Web of Science ®Google Scholar
• Im DD, Chary A, Condella AL, et al. Emergency department clinicians’ attitudes toward opioid use disorder and emergency department-initiated buprenorphine treatment: a mixed-methods study. West J Emerg Med. 2020;21(2):261–271.
   PubMed Web of Science ®Google Scholar
• Guerrero E, Ober AJ, Howard DL, et al. Organizational factors associated with practitioners’ support for treatment of opioid use disorder in the emergency department. Addict Behav. 2020;102:106197.
   PubMed Web of Science ®Google Scholar
• Calcaterra SL, Binswanger IA, Edelman EJ, McNair BK, Wakeman SE, O’Connor PG. The impact of access to addiction specialist on attitudes, beliefs and hospital-based opioid use disorder related care: a survey of hospitalist physicians. Substance Abuse. 2020;1–9.
   PubMed Web of Science ®Google Scholar
• McGinty EE, Stone EM, Kennedy-Hendricks A, Bachhuber MA, Barry CL. Medication for opioid use disorder: a national survey of primary care physicians. Ann Intern Med. 2020;173(2):160–162.
   PubMed Web of Science ®Google Scholar
• Haffajee RL, Andraka-Christou B, Attermann J, Cupito A, Buche J, Beck AJ. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder. Subst Abuse Treat Prevent Policy. 2020;15(69):1–13.
   PubMedGoogle Scholar
• Jones J, Tierney M, Jacobs G, Chien SY, Mallisham S. Empowering psychiatric mental health nurse practitioners to expand treatment opportunities for veterans with opioid use disorder. J Addict Nurs. 2020;31(4):261–268.
   PubMed Web of Science ®Google Scholar
• Kennedy-Hendricks A, Barry CL, Stone E, Bachhuber MA, McGinty EE. Comparing perspectives on medication treatment for opioid use disorder between national samples of primary care trainee physicians and attending physicians. Drug Alcohol Depend. 2020;216:108217.
   PubMed Web of Science ®Google Scholar
• Schultz JMO. Acceptance of Primary Care Providers Acquiring Buprenorphine Waivers for Opioid Use Disorder Population in Rural Upstate New York [dissertation]. Binghamton, NY: State University of New York at Binghamton; 2020.
   Google Scholar
• Brackett CD, Duncan M, Wagner JF, Fineberg L, Kraft S. Multidisciplinary treatment of opioid use disorder in primary care using the collaborative care model. Subst Abuse. 2021;1–5.
   Google Scholar
• Lien IRC, Seaton R, Szpytman A, et al. Eight-hour medication-assisted treatment waiver training for opioid use disorder: integration into medical school curriculum. Medical Education Online. 2021;26(1):1847755–1847754.
   PubMed Web of Science ®Google Scholar
• Oros SM, Christon LM, Barth KS, Berini CR, Padgett BL, Diaz VA. Facilitators and barriers to utilization of medications for opioid use disorder in primary care in South Carolina. Int J Psychiatry Med. 2021;56(1):14–39.
   PubMed Web of Science ®Google Scholar
• Mort SC, Diaz SR, Beverly EA. Using contact-based education to destigmatize opioid use disorder among medical students. Teach Learn Med. 2021;33(2):196–209.
   PubMed Web of Science ®Google Scholar
• Zuckerman M, Kelly T, Heard K, Zosel A, Marlin M, Hoppe J. Physician attitudes on buprenorphine induction in the emergency department: results from a multistate survey. Clin Toxicol. 2021;59(4):279–285.
   PubMed Web of Science ®Google Scholar
• Shuey B, Lee D, Ugalde I, et al. Evaluation of resident physicians’ knowledge of and attitudes towards prescribing buprenorphine for patients with opioid use disorder. J Addict Med. 2021;15(3):219–225.
   PubMed Web of Science ®Google Scholar
• Caplehorn JR, Dalton MS, Haldar F, Petrenas A-M, Nisbet JG. Methadone maintenance and addicts’ risk of fatal heroin overdose. Subst Use Misuse. 1996;31(2):177–196.
   PubMed Web of Science ®Google Scholar
• Knudsen HK, Knudsen HK, Ducharme LJ, Roman PM. Research network involvement and addiction treatment center staff: counselor attitudes toward buprenorphine. Am J Addict. 2007;16(5):365–371.
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Kanter GP, Donelan K. Institutional substance use disorder intervention improves general internist preparedness, attitudes, and clinical practice. J Addict Med. 2017;11(4):308–314.
   PubMed Web of Science ®Google Scholar